

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention

INHIBITION OF GENE EXPRESSION IN VERTEBRATES USING DOUBLE-STANDED RNA (RNAi)

As the below named inventor(s), I/we declare that:

The declaration is directed to:

☐

The attached application, or

☒

Application No. 10/602,235, filed on 06/24/2003,

☐

as amended on _____ (if applicable).

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME(S) OF INVENTORS:

Inventor one: Olga A. Cabello

Signature: *Olga A. Cabello*

Date: 12-05-03

Citizen of: US US

Inventor two: Paul A. Overbeek

Signature: *Paul A. Overbeek*

Date: 12-5-03

Citizen of: _____ US

Inventor three: _____

Signature: _____

Date: _____

Citizen of: _____

Inventor four: _____

Signature: _____

Date: _____

Citizen of: _____

☐

Additional inventors are being named on _____ additional form(s) attached hereto.

Declaration for Utility or Design Patent Application

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER 147055968US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 12/8/03

Signature: *Staci Harris*

(*Staci Harris*)
(*Monica Thomas*)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER 147055968US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 8, 2003

Signature:

Staci U Harris
(Staci Harris)

Docket No.: HO-P02494US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Patent Application of:
Olga A. Cabello, et al.

Application No.: 10/602,235

Filed: June 24, 2003

Art Unit: N/A

For: INHIBITION OF GENE EXPRESSION IN
VERTEBRATES USING DOUBLE-
STRANDED RNA (RNAi)

Examiner: Not Yet Assigned

POWER OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Baylor College of Medicine, assignee of the entire right title and interest in the above-identified application by assignment dated December 5, 2003, submitted herewith, hereby appoints the following attorneys and/or agents of the firm of Fulbright & Jaworski L.L.P.:

All practitioners at Customer Number 26271.

as its attorneys with full power of substitution to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith.

The assignee certifies that it has reviewed the assignment and to the best of the assignee's knowledge and belief, title is in the assignee.

Application No.: 10/602,235

Docket No.: HO-P02494US1

Please direct all correspondence regarding this application to the following:

FULBRIGHT & JAWORSKI L.L.P.

Attn: Melissa L. Sistrunk


1301 McKinney, Suite 5100

Houston, Texas 77010-3095

Telephone: (713) 651-5151

Fax: (713) 651-5246

For: Baylor College of Medicine



W. Dalton Tomlin
Senior Vice President & General Counsel

Dated: _____

